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ABSTRACT
BACKGROUND The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous
coronary intervention (PCI) with drug-eluting stent (DES) implantation are unclear.
OBJECTIVES This study sought to characterize the determinants and consequences of PDB after PCI.
METHODS The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study was
used to determine the incidence and predictors of clinically relevant bleeding events occurring within 2 years after
hospital discharge. The effect of PDB on subsequent 2-year all-cause mortality was estimated by time-adjusted Cox
proportional hazards regression.
RESULTS Among 8,582 “all-comers” who underwent successful PCI with DES in the ADAPT-DES study, PDB occurred
in 535 of 8,577 hospital survivors (6.2%) at a median time of 300 days (interquartile range: 130 to 509 days)
post-discharge. Gastrointestinal bleeding (61.7%) was the most frequent source of PDB. Predictors of PDB included
older age, lower baseline hemoglobin, lower platelet reactivity on clopidogrel, and use of chronic oral anticoagulation
therapy. PDB was associated with higher crude rates of all-cause mortality (13.0% vs. 3.2%; p < 0.0001). Following
multivariable adjustment, PDB was strongly associated with 2-year mortality (hazard ratio [HR]: 5.03; p < 0.0001), with
an effect size greater than that of post-discharge myocardial infarction (PDMI) (HR: 1.92; p ¼ 0.009).
CONCLUSIONS After successful PCI with DES in an unrestricted patient population, PDB is not uncommon and has
a strong relationship with subsequent all-cause mortality, greater that that associated with PDMI. Efforts to reduce
PDB may further improve prognosis after successful DES implantation. (Assessment of Dual Antiplatelet Therapy With
Drug-Eluting Stents [ADAPT-DES]; NCT00638794) (J Am Coll Cardiol 2015;66:1036–45) © 2015 by the American
College of Cardiology Foundation.
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he optimal duration of dual antiplatelet

enrollment, regardless of clinical presenta-

ABBREVIATIONS

therapy (DAPT) after percutaneous coronary

tion or lesion complexity. The only major

AND ACRONYMS

intervention (PCI) with drug-eluting stents

exclusion criteria were the occurrence of a

(DES) remains a matter of active debate (1–3). While

major complication during the procedure or

DAPT is effective in preventing stent-related and

before platelet function testing, or if bypass

non–stent-related adverse ischemic events (4), pro-

surgery was planned after PCI. Platelet

longed DAPT use is associated with a substantial

reactivity on aspirin and clopidogrel was

risk of bleeding and possibly increased mortality

assessed after an adequate loading period to

(5,6). Periprocedural bleeding after PCI has been

ensure full antiplatelet effect using the Ver-

shown to be associated with increased short-term

ifyNow Aspirin, P2Y12, and IIb/IIIa assays

intervention

and long-term morbidity and mortality across the

(Accumetrics Inc., San Diego, California) (11).

PDB = post-discharge bleeding

entire clinical spectrum of patients with coronary ar-

After PCI, patients were treated with aspirin

tery disease treated with PCI (7–9).

indeﬁnitely, and clopidogrel was recom-

myocardial infarction

mended for at least 1 year. All other treat-

PRU = P2Y12 reactivity units

ments were per standard of care. Clinical

ST = stent thrombosis

SEE PAGE 1046

In

contrast,

the

impact

and

DAPT = dual antiplatelet
therapy

DES = drug-eluting stent(s)
MACE = major adverse cardiac
event(s)

MI = myocardial infarction
PCI = percutaneous coronary

PDMI = post-discharge

contribution

follow-up was scheduled at 30 days, 1 year,

of nonperiprocedural bleeding events to late mor-

and 2 years. An independent clinical events

tality is less certain, especially when compared to

committee blinded to VerifyNow results adjudicated

post-discharge ischemic events such as myocardial

all events using original source documents. The

infarction (MI) (4,10). Therefore, we sought to

institutional review board at each participating cen-

evaluate the incidence, predictors, and impact of

ter approved the study, and all eligible patients

clinically signiﬁcant bleeding occurring after hospi-

signed written informed consent prior to enrollment.

tal discharge following successful DES implantation

For the present study, patients included in the

from the large-scale ADAPT-DES (Assessment of

ADAPT-DES study were compared according to the

Dual Antiplatelet Therapy With Drug-Eluting Stents)

occurrence of post-discharge bleeding (PDB) at 2

study.

years.

METHODS

STUDY OBJECTIVES AND DEFINITIONS. The objec-

TVF = target vessel failure

tives of the present study were to: 1) determine the
STUDY POPULATION. The ADAPT-DES study was

incidence of PDB in patients who were in-hospital

a

speciﬁcally

event-free after PCI with DES; 2) identify risk factors

designed to determine the association between pla-

associated with the occurrence of PDB; and 3) eval-

telet reactivity and stent thrombosis (ST) after DES.

uate the time-dependent, multivariable adjusted

The design and major outcomes of the ADAPT-DES

effect of PDB on mortality within 2 years after the

study have been previously described (11). In brief,

index procedure.

prospective,

multicenter

registry

an “all-comers” population of 8,582 patients were

PDB was deﬁned as the occurrence of any of the

prospectively enrolled at 11 sites in U.S. and European

following: a Thrombolysis In Myocardial Infarction

hospitals. All patients successfully treated with

(TIMI) major or minor bleed; a Global Use of Strate-

1 or more DES and who were adequately loaded

gies to Open Occluded Arteries (GUSTO) severe or

with

moderate bleed; an Acute Catheterization and Urgent

aspirin

and

clopidogrel

were

eligible

for
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Intervention Triage Strategy (ACUITY) major bleed;
or any PDB event requiring medical attention.

F I G U R E 1 Bleeding Rates After Percutaneous Coronary

Intervention

According to its timing, PDB was deﬁned as early
(<30 days), late (30 days to <1 year), or very late

10

(1 to 2 years). The following pre-speciﬁed categories
were used to group the site of bleeding: gastrointestinal, genitourinary, central nervous system, retroperitoneal, arterial access-site (nonretroperitoneal),
and other.
Endpoints

evaluated

in

the

present

study

included all-cause mortality, cardiac mortality, MI,

Bleeding Events (%)

1038

All bleedings
Bleedings without transfusion
Bleedings with transfusion

8

6.6%

6

4.7%

4
2

2.1%

deﬁnite or probable ST, target vessel failure (TVF),
and major adverse cardiac events (MACE). MI was
deﬁned according to the ACUITY criteria (11,12).

0
0

3

6

9
12
15
18
Months After Discharge

21

24

Deﬁnite or probable stent thrombosis was deﬁned
according to the Academic Research Consortium

Cumulative rates of ﬁrst post-discharge bleeding event increased

deﬁnition (13). TVF was deﬁned as the composite of

over time in all patients; a similar pattern was seen when patients

death, MI, or ischemia-driven target vessel revascu-

were stratiﬁed according to requirement for blood transfusion.

larization. MACE was deﬁned as the composite of
cardiac death, MI, or ischemia-driven target lesion
gastrointestinal (Figure 2). Among those experi-

revascularization.

encing bleeding, 168 (31.4%) required a blood
STATISTICAL ANALYSIS. Descriptive statistics are

presented as mean  SD and were compared with
the Student t test; categorical variables are reported

transfusion for treatment. Median time to ﬁrst PDB
was 300 days (interquartile range: 130 to 509 days).
Risk of bleeding accrued constantly over time, and

as percentages and were tested with the chi-square

the rates of ﬁrst bleeding at 30 days, 1 year, and

test. Event rates during follow-up were estimated

2 years were 0.7%, 3.8%, and 8.8%, respectively.

by Kaplan-Meier methods. Unadjusted hazard ratios

The proportions of ﬁrst PDB events in the early

for 2-year outcomes were determined from Cox

(<30 days), late (30 days to 1 year), and very late

proportional hazards models with time-dependent

(>1 year) period were 10.5%, 48.2%, and 41.3%,

bleeding as the only covariate. Adjusted hazard ra-

respectively.

tios were estimated from multivariable Cox models
selected by a stepwise process with entry and exit
thresholds set to 0.1. Both PDB and post-discharge MI
(PDMI) were modeled as time-dependent covariates.
All

modeling

assumptions

were

checked

and

addressed. The effect size of PDB and PDMI were
directly compared using the Wald test, controlling for
other covariates. Statistical analyses were performed
in SAS version 9.4 (SAS Institute, Cary, North Carolina)
and plots were constructed in R (version 3.1.2) using
ggplot2 (version 1.0.0).

PREDICTORS OF BLEEDING. Per baseline clinical

characteristics (Table 1), patients who had PDB within
2 years were older and more commonly female, and
had a higher proportion of hypertension, hyperlipidemia, peripheral arterial disease, congestive heart
failure, previous MI, and previous coronary revascularization. Patients who experienced PDB also had
lower levels of baseline hemoglobin and creatinine
clearance.
When comparing procedural characteristics (Table 1),
patients with PDB were more likely to have multivessel and left main coronary artery disease and more

RESULTS

frequent treatment of calciﬁed and bifurcation lesions
than those in the no-PDB group. Patients with PDB

INCIDENCE AND SITES OF POST-DISCHARGE BLEEDING.

had a greater number of lesions treated, longer le-

Among the 8,582 patients enrolled in the ADAPT-

sions, and longer stents. There were no signiﬁcant

DES study who underwent PCI with DES, 8,577

differences in median [Q1 to Q3] baseline P2Y 12 reac-

were discharged alive and included in the current

tivity units (PRU) on clopidogrel (PDB 188 [97 to 264]

analysis. Median follow-up was 729 days (inter-

vs. 188 [114 to 260]; p ¼ 0.83) or aspirin reactivity units

quartile range: 703 to 730 days). During follow-up,

(400 [387 to 432] vs. 400 [388 to 424]; p ¼ 0.79) be-

535 patients (6.2%) had a total of 662 PDB events

tween the PDB and no-PDB groups, respectively.

(Figure 1); 82 patients (15.3%) had multiple bleeding
events.

The

most

common

site

of

PDB

was

Baseline characteristics in patients with PDB
according to the need for blood transfusion are
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reported in Online Table 1. Patients with PDB and
blood transfusions were more commonly female,

F I G U R E 2 Site of Post-Discharge Bleeding

had lower baseline hemoglobin levels, and had a

61.7%

higher proportion of chronic kidney disease at basetransfusions.
In reviewing medications used in patients with
and without PDB (Online Table 2), patients with PDB
more

commonly

treated

with

oral

anti-

coagulation with warfarin and proton pump in-

60
Bleeding Events (%)

line compared to patients with PDB not requiring

were

1039
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40

20

12.2%

8.6%

7.4%

7.0%

38/444

33/444

31/444

3.2%

hibitors, and less commonly on DAPT during the

274/444

54/444

entire study period. Speciﬁcally, patients experi-

0

encing PDB had higher rates of DAPT disruption

Gastrointestinal Peripheral Genitourinary

CNS

because of bleeding (29.0% vs. 1.6%; p < 0.0001).

14/444

Access Retroperitoneal
Site

Also, statin use during 2-year follow-up was lower in
patients with PDB, but there were no differences in
nonsteroidal anti-inﬂammatory drug use between

Among 444 patients with bleeding and speciﬁed source, gastrointestinal bleeding was the
most predominant cause of post-discharge bleeding. CNS ¼ central nervous system.

groups.
The multivariable adjusted independent predictors
of PDB within 2-year follow-up were older age, pe-

comers patient population (Central Illustration). The

ripheral artery disease, lower baseline hemoglobin

main ﬁndings of the present analysis include: 1) PDB

levels, lower baseline PRU, and warfarin use at

requiring medical attention was not uncommon and

discharge. Treatment of heavily calciﬁed lesions and

increased monotonically throughout the 2-year post-

bifurcations were also independent predictors of PDB

PCI follow-up period; 2) clinical and pharmacologic

(Table 2).

risk factors, including lower PRU and concomitant

2-YEAR CLINICAL OUTCOMES AND PREDICTORS OF

oral anticoagulation use, were strongly associated

ALL-CAUSE MORTALITY. Unadjusted 2-year clinical

with the risk of PDB; and 3) PDB with or without

outcomes according to the occurrence of PDB are re-

associated transfusion was strongly associated with

ported in Table 3. Patients experiencing PDB had

subsequent mortality, with an adjusted hazard

higher crude rates of all-cause mortality (13.0% vs.

greater than that for PDMI.

3.2%; p < 0.0001) (Figure 3A) as well as higher rates of

In the all-comers ADAPT-DES population, PDB

cardiac mortality (5.1% vs. 1.9%; p < 0.0001)

occurred in approximately 1 of every 15 patients

(Figure 3A), MI, ST, TVF, and MACE. PDB occurring

within 2 years of follow-up, with more than 50% of

between 30 days and 1 year or 1 year and 2 years were

PDB events occurring beyond 300 days. In a time-

both associated with increased mortality (Figure 3B).

adjusted multivariable analysis (accounting for the

Patients who had PDB and received blood trans-

timing of occurrence of bleeding and MI events),

fusions had the highest rates of 2-year all-cause and

PDB was not only more frequent than PDMI (662

cardiac mortality (Figure 4).

PDB events compared with 391 PDMI events), but

By multivariable analysis, PDB was the strongest

also was associated with an approximate 2.6-fold

predictor of 2-year mortality (hazard ratio: 5.03; 95%

greater risk of subsequent mortality. These data

conﬁdence interval: 3.29 to 7.66; p < 0.0001)

extend prior reports demonstrating that the risk of

(Table 4). The effect of PDB with or without trans-

bleeding is at least as prognostically important as

fusion on mortality was similar. The magnitude of the

MI (2,4–6,10). The ongoing risk and strong associa-

effect of PDB on subsequent mortality was roughly

tion between PDMI and mortality may underlie the

2.6-fold greater than the effect of PDMI (hazard ratio:

recent ﬁndings from randomized trials that shorter

1.92; 95% conﬁdence interval: 1.18 to 3.12; p ¼ 0.009)

DAPT duration may result in improved survival

(p ¼ 0.008 for the effect size of PDB vs. PDMI).

compared to prolonged DAPT, presumably by minimizing

DISCUSSION

bleeding-related

complications

(3,5,6).

Nonetheless, some patients at high risk for thrombotic events, such as those with prior MI, might still

The current report, drawn from 8,577 patients un-

beneﬁt from more potent and prolonged DAPT

dergoing successful PCI with DES, is the largest

(2,14). Choosing those patients who may beneﬁt

contemporary study to evaluate the incidence, pre-

from shorter versus longer DAPT requires balancing

dictors, and prognostic impact of PDB in an all-

the risk of future atherothrombotic events and
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T A B L E 1 Baseline Clinical and Procedural Characteristics

T A B L E 2 Independent Predictors of PDB Within 2 Years

PDB (n ¼ 535)

No PDB
(n ¼ 8,042)

p Value

67.0  10.4

63.4  10.8

<0.0001

373 (69.7)

5,982 (74.4)

0.02

White

489 (91.4)

7,111 (88.4)

0.04

Bifurcation lesion

1.32 (1.06–1.64)

0.01

Body mass index, kg/m2

29.0  6.3

29.5  5.7

0.09

Platelet reactivity units
(per 10-unit decrease)

1.01 (1.01–1.02)

0.002

Baseline hemoglobin
(per g/dl decrease)

1.28 (1.22–1.37)

<0.0001

Variable*

Clinical characteristics
Age, yrs
Male

Diabetes mellitus

193 (36.1)

2,588 (32.2)

0.06

Hypertension

461 (86.2)

6,368 (79.2)

0.0001

Hyperlipidemia

427 (79.8)

5,949 (74.0)

0.003

Current smoker

111 (20.7)

1,829 (22.7)

0.29

Previous MI

158 (29.5)

2,006 (24.9)

0.02

Previous PCI

0.0007

HR (95% CI)

p Value

Age (per yr increase)

1.02 (1.01–1.03)

<0.0001
<0.0001

Warfarin, at discharge

2.31 (1.78–2.99)

Peripheral artery disease

1.57 (1.25–1.98)

0.0001

Calciﬁed lesion

1.25 (1.05–1.50)

0.01

*The candidate covariates considered for inclusion in the model were: in-hospital
bleeding, age, male sex, diabetes, hypertension, hyperlipidemia, congestive heart
failure, peripheral arterial disease, creatinine clearance, pervious percutaneous
coronary intervention, ST-segment elevation MI, baseline hemoglobin, warfarin at
discharge, triple vessel disease, left main disease, coronary calciﬁcation, bifurcation, chronic total occlusion, number of vessels treated, number of lesion treated,
stents implanted, mechanical closure device used, P2Y12 reactivity units, and
aspirin reactivity units.

267 (49.9)

3,411 (42.4)

Previous CABG

113 (21.1)

1,354 (16.8)

0.01

Peripheral arterial disease

92 (17.2)

782 (9.7)

<0.0001

Renal insufﬁciency

87 (16.3)

571 (7.1)

<0.0001

24 (4.5)

114 (1.4)

<0.0001

Congestive heart failure

69 (12.9)

630 (7.8)

<0.0001

Ejection fraction, %

55.0  13.71

54.9  12.34

0.91

199 (37.2)

2,376 (29.5)

0.0002

Stable coronary artery disease

278 (52.0)

3,871 (48.1)

0.09

bleeding risk. In this regard, some factors associated

Acute coronary syndrome

257 (48.0)

4,171 (51.9)

0.08

with increased risk of bleeding identiﬁed in the

Unstable angina

147 (27.5)

2,219 (27.6)

0.95

present report also have been associated with future

Non–ST-segment elevation MI

80 (15.0)

1,168 (14.5)

0.79

ischemic events (e.g., advanced age, peripheral

ST-segment elevation MI

30 (5.6)

784 (9.7)

0.002

arterial disease, stenting of complex lesions) (15–17).

13.3  1.6

14.0  1.5

<0.0001

228.7  70.4

226.6  62.5

White blood cell count, 10 /ml

8.30  4.85

7.93  3.05

0.08

Creatinine clearance, ml/min*

83.0  40.0

94.8  37.1

<0.0001

Dialysis

Ejection fraction <40%

CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; PDB ¼
post-discharge bleeding.

Clinical presentation

Hemoglobin, g/dl
3

Platelet count, 10 /dl
3

0.51

of

oral

anticoagulation.

352 (4.4)

0.93

plantation, although this decision-making process

14 (0.2)

0.02

will remain challenging in some cases, and must

170 (31.8)

3,112 (38.7)

0.001

174 (32.5)

2,659 (33.1)

0.80

Radial

23 (4.3)

Brachial

4 (0.7)

1
2

Number of diseased vessels

Number of stents per patient

use

decisions should improve outcomes after DES im-

7,676 (95.4)

Total lesion length, mm

concomitant

0.60

508 (95.0)

3

and

bleeding risk proﬁle to personalize DAPT duration

Vascular access site

Number of lesions per patient

with greater bleeding risk, such as baseline anemia
Considering the individual patient’s thrombotic and

Angiographic and procedural characteristics
Femoral

Other variables, however, are uniquely associated

incorporate patient preferences.
The relationship between PDB and mortality is

0.0002

likely multifactorial (Central Illustration), including:

0.1

1) decrease in circulating blood volume and oxygen-

0.01

carrying capacity

1.7  1.0

0.009

propensity to ischemia and arrhythmias; 2) discon-

191 (35.7)

2,271 (28.2)

1.6  0.8

1.5  0.8

29.2  21.0

26.9  20.0

1.8  1.1

resulting

in

hypotension

and

35.0  23.4

32.3  22.3

0.006

tinuation of DAPT to manage bleeding, which

Pre-procedural TIMI ﬂow 0/1

40 (7.5)

748 (9.3)

0.15

Post-procedural TIMI ﬂow 3

compared to DAPT discontinuation for other reasons

530 (99.1)

7,995 (99.4)

0.40

Thrombus

69 (12.9)

1,213 (15.1)

0.17

Calciﬁed lesion

211 (39.4)

2,433 (30.2)

<0.0001

Bifurcation lesion

104 (19.4)

1,222 (15.2)

0.008

the ﬁrst 30 days (18,19); 3) discontinuation of other

33 (6.2)

372 (4.6)

0.10

life-extending medications to treat hypotension after

Left anterior descending artery

242/658 (36.8)

3,707/9,450 (39.2)

0.21

converting enzyme inhibitors, which paradoxically

Right coronary artery

202/658 (30.7)

2,984/9,450 (31.6)

0.63

often are not restarted after patient stabilization;

36/658 (5.5)

283/ 9,450 (3.0)

208 (38.9)

3153 (39.2)

Total stent length, mm

Chronic total occlusion

has been strongly associated with a higher risk of
thrombotic events, especially when occurring within

bleeding, such as beta-blockers and angiotensin-

Location†

Left main coronary artery
Intravascular ultrasound use

0.0004
0.89

Values are n (%) or mean  SD. *Calculated by Cockcroft-Gault formula. †Lesion-level analysis, reported as
n/total lesion N (%).
CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
TIMI ¼ Thrombolysis In Myocardial Infarction.

and 4) administration of red blood cell transfusions
and other blood products that have been associated
with systemic vasoconstriction, activation of inﬂammatory pathways, apoptosis, increased platelet
aggregation, and thrombosis (20). An interesting
ﬁnding of the current report is that PDB without
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transfusion was associated with a similar adjusted
hazard for mortality as PDB with transfusion. This

T A B L E 3 2-Year Outcomes According to PDB Occurrence

PDB
(n ¼ 535)

No PDB
(n ¼ 8,042)

Unadjusted
HR (95% CI)

p Value*

13.0 (68)

3.2 (243)

8.14 (5.53–12.00)

<0.0001

Cardiac

5.1 (25)

1.9 (144)

4.95 (2.64–9.28)

<0.0001

Noncardiac

6.1 (31)

1.2 (87)

10.52 (5.89–18.81)

<0.0001

observation may be considered counterintuitive, as
patients receiving transfusions are often sicker,
with multiple comorbidities and greater extent of
bleeding (21). In our study, prior to accounting for

All-cause mortality

differences in baseline features, PDB with trans-

MI

fusion was associated with greater cardiac and all-

Target vessel failure

cause

Deﬁnite/probable Stent thrombosis

mortality

than

1041
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PDB

without

transfusion.

However, after multivariable adjustment, an independent detrimental effect of transfusion was no
longer present in patents with PDB, suggesting that
it is the deleterious effects of bleeding itself

MACE†

13.5 (68)

4.1 (319)

3.14 (2.02–4.90)

<0.0001

20.6 (103)

9.0 (685)

2.59 (1.83–3.68)

<0.0001

1.5 (8)

1.0 (81)

3.63 (1.29–10.24)

24.1 (123)

9.9 (758)

2.89 (2.10–3.97)

0.02
<0.0001

Event rates are Kaplan-Meier estimates reported as % (n). *Wald p value. †Composite of cardiac death, MI, or
target lesion revascularization.
MACE ¼ major adverse cardiac event(s); other abbreviations as in Table 1.

(perhaps in concert with essential medication discontinuation) rather than transfusions that may
Early discontinuation of or removing aspirin

affect prognosis.
Not surprisingly, concomitant use of oral antico-

entirely from the DAPT regimen may reduce bleeding

agulants (22) and lower levels of PRU on clopi-

in patients at high risk for hemorrhagic complica-

dogrel (signifying greater inhibition of adenosine

tions, as suggested in a recent modest-sized trial in

diphosphate–associated

noncomplex post-PCI patients with atrial ﬁbrillation

platelet

activation)

were

strongly associated with development of PDB. This

requiring warfarin

latter observation suggests a possible role for careful

consistent

with

anticoagulation (29). This is

the

ADAPT-DES

study,

which

agent selection and/or dose modiﬁcation of agents
that block the platelet P2Y12 integrin receptor in

F I G U R E 3 All-Cause and Cardiac Mortality According to PDB

patients at high bleeding risk (e.g., the elderly, those
with recent bleeding, or atrial ﬁbrillation requiring
oral anticoagulation). The association between PRU

Post-discharge bleeding

A

clinical utility in using PRU to guide treatment decisions. Given the higher rate and prognostic impact
of PDB compared to PDMI, coupled with the im-

9
6

study

suggests

that

future

0
0

in-

vestigations might explore the role of PRU monitoring in high bleeding risk patients to ensure that
P2Y12 receptor-mediated platelet inhibition is not
greater than necessary.

B

tinal bleeding was the most frequent identiﬁable
source of PDB. Interestingly, proton pump inhibitors
were used relatively infrequently at discharge, and at
1 year their use was slightly more common in the
group with PDB, likely a response to the bleed. As

12
15
18
9
Months After Discharge

21

24

8
6.8%
6

6.4%

4
p = 0.45
2
0

proton pump inhibitors have been shown to signiﬁ-

30

p <0.0001
1.4%

0.4%
0.2%
0 30

cantly reduce gastrointestinal bleeding in patients
with selected risk factors (28), more liberal prophy-

6

PDB 535 529 520 506 492 480 467 461 289
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739

Consistent with prior studies (10,27), gastrointes-

lactic use of these agents during DAPT treatment may

3

Number at risk

All-Cause Mortality (%)

our

5.1%
3.2%
1.9%

3

proved safety proﬁle of current generation DES
(19,25,26),

13.0%

12

Mortality (%)

(23,24), although no prospective study has yet shown

p <0.0001 p <0.0001

and late bleeding has been previously demonstrated

No post-discharge bleeding

15

90

p <0.0001
1.7%

180 270 365 365 450 540 630 720
Days Since Discharge

Number at risk

PDB
No PDB

535
532 529 520 506 489 480 467 461 265
8,042 7,935 7,840 7,795 7,756 7,619 7,446 7,369 7,306 4,407

improve patient prognosis. Moreover, the predominance of gastrointestinal bleeding highlights the need
for judicious screening (e.g., careful history, selective

Kaplan-Meier estimates demonstrate higher rates of all-cause mortality (solid line) and
cardiac mortality (dotted line) according to the occurrence of post-discharge bleeding

use of gastroscopy and colonoscopy) in appropriate

(PDB) (salmon) compared to no PDB (blue) over 2 years of follow-up (A) as well as the

patients before elective PCI involving DES implanta-

landmark analysis at 30-day and 1-year follow-up (B).

tion requiring prolonged DAPT.
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T A B L E 4 Independent Predictors of All-Cause Mortality at

F I G U R E 4 Mortality According to PDB and Need for Transfusion

2 Years

A
All-Cause Mortality (%)

18

Adjusted HR
(95% CI)

Variable*

16.2%

15
12

Log Rank p <0.0001

11.6%

9
6
3.2%

3
0
0

3

6

9
12
15
18
Months Since Discharge

21

24

Number at risk
PDB with transfusion 168
167
162 160
154
150 144 140
77
321
211
PDB without transfusion 367 362 358 346 338 330 323
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739

B

p Value

5.03 (3.29–7.66) <0.0001

PDB†
With transfusion

4.71 (2.76–8.03) <0.0001

Without transfusion

5.27 (3.32–8.35) <0.0001

Post-discharge MI†

1.92 (1.18–3.12)

0.009

Current smoker

1.69 (1.25–2.29)

0.001

Age (per yr increase)

1.04 (1.02–1.05) <0.0001

Male

1.45 (1.11–1.90)

0.007

Diabetes mellitus

1.48 (1.17–1.88)

0.001

Previous MI

1.42 (1.12–1.81)

0.004

STEMI or non-STEMI presentation

1.41 (1.10–1.83)

0.008

VerifyNow P2Y12 reactivity units >208

1.22 (0.96–1.54)

0.10

IVUS use

0.83 (0.65–1.06)

0.13

Creatinine clearance
(per ml/min increase)‡

0.99 (0.99–1.00)

0.0007

Baseline white blood cells
(per 103/ml increase)

1.03 (1.01–1.04)

<0.0001

Baseline hemoglobin (per g/dl increase) 1.18 (1.09–1.28) <0.0001

Cardiac Mortality (%)

8
7.0%

6
4.3%

4

Log Rank p <0.0001

2

1.9%

*The candidate covariates considered for inclusion in the model were: PDB,
post-discharge MI, age, male, diabetes, current smoker, previous MI, baseline
presentation with ST-segment elevation MI (STEMI) or non-STEMI (vs. stable
coronary artery disease), hyperlipidemia, baseline hemoglobin, baseline white
blood cells, baseline platelets, creatinine clearance, VerifyNow P2Y12 reactivity
units >208, and intravascular ultrasound (IVUS) guidance. †Both variables were
included as time-dependent covariates. ‡Calculated by the Cockcroft-Gault
formula.
Abbreviations as in Table 1.

0
0

3

6

9
12
15
18
Months Since Discharge

21

24

Number at risk
PDB with transfusion 168
167
162 160 154
150 144 140
77
PDB without transfusion 367 362 358 346 338 330 323
321
211
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739
Post-discharge bleeding
with transfusion

Post-discharge bleeding
without transfusion

No post-discharge
bleeding

STUDY LIMITATIONS. Our study has several strengths

relative to prior similar investigations, including its
large size, prospective nature, recruitment of an allcomers population (resulting in higher PDB rates
than in previous studies) (4,10), and assessment of
platelet

reactivity

to

aspirin

and

clopidogrel.

Conversely, our study has several limitations. First,
Kaplan-Meier estimates of (A) all-cause mortality and (B) cardiac mortality according to
post-discharge bleeding (PDB) occurrence and requirement (or not) of blood transfusion
demonstrate that early after percutaneous coronary intervention, individuals with PDB

bleeding events were not independently adjudicated
by a blinded clinical events committee, introducing

needing blood transfusions experience lower or comparable rates of mortality compared to

potential reporting bias. It is possible that minor

those with no transfusions, but those rates cross between 9 and 12 months and climb more

bleeding events were under-reported. Second, the

sharply thereafter.

source of bleeding was not obtained in all patients.
Third, the present study was a post hoc analysis from
the ADAPT-DES study, and as such should be considsuggested that aspirin resistance was protective from

ered hypothesis generating. Fourth, patients with

major bleeding after DES implantation without

major periprocedural complications were excluded

affecting MI or stent thrombosis rates (11). However,

from the ADAPT-DES study, which while representing

given the well-established role of aspirin in secondary

a small proportion of contemporary cases, may

prevention after acute coronary syndrome and in

represent a high-risk group for subsequent bleeding

patients with vascular disease (30), large-scale ran-

and MI. Fifth, prasugrel only became available late

domized trials are required before aspirin withdrawal

during the ADAPT-DES study recruitment, and tica-

can be routinely recommended. Several such trials

grelor was unavailable; as a result almost all patients

involving agents such ticagrelor and novel oral anti-

were treated with clopidogrel. Use of novel, more

coagulant drugs are ongoing that might provide

potent antithrombotic regimens, however, would

insight to this issue (NCT02270242; NCT01813435;

have most likely resulted in an increase in PDB and a

NCT01830543; NCT02164864).

decrease in PDMI, further reinforcing our ﬁndings

Downloaded for library services (libraryservices@lvhn.org) at Lehigh Valley Health Network from ClinicalKey.com by Elsevier on
August 26, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Généreux et al.

JACC VOL. 66, NO. 9, 2015
SEPTEMBER 1, 2015:1036–45

Post-Discharge Bleeding After PCI

CENTRAL I LLU ST RAT ION Post-Discharge Bleeding After PCI: Predictors and Impact of
Clinically Signiﬁcant Bleeding on Mortality

Clinical bleeding predictors:
Atherosclerosis risk factors
History of previous bleeding
Anemia
Chronic kidney disease
Low platelet reactivity

Pharmacological bleeding predictors:
Oral anticoagulation
Prolonged dual antiplatelet therapy
(DAPT)
High-potency DAPT

BLEEDING

DAPT
discontinuation

Blood
extravasation

Blood
transfusion

Rebound platelet
reactivity

Hemoglobin drop
Hypovolemia/
hypotension

Transfusion-related
effects
Inflammatory
cascade activation

+
Incomplete stent
endothelialization

Vasoconstriction
Decreased
oxygen delivery

Platelet
aggregation

Cardiac or
cerebrovascular event

Atherothrombotic event (stent
thrombosis/myocardial infarction)

DEATH

Généreux, P. et al. J Am Coll Cardiol. 2015; 66(9):1036–45.

Pathophysiological mechanisms linking out-of-hospital clinically signiﬁcant bleeding and mortality after implantation of drug-eluting stents
(DES). Several clinical and pharmacological factors increase the propensity for bleeding under dual antiplatelet therapy (DAPT). Hemorrhagic
events lead to mortality through a direct effect (central pathway) by reducing circulating blood volume as well as reducing blood oxygencarrying capacity and tissue hypoxia; and through indirect effect (lateral pathways) by increasing the risk for stent thrombosis (because of
sudden DAPT discontinuation with rebound in platelet reactivity while the DES is still partially endothelialized) as well as cardiac and
noncardiac ischemic events associated with increased thrombogenicity after blood transfusions. Preventing out-of-hospital bleeding after DES
implantation may signiﬁcantly improve survival and long-term prognosis after percutaneous coronary revascularization (PCI).

(31,32). Finally, although we performed a rigorous

magnitude of the effect of PDB on 2-year mortality

multivariable time-adjusted analysis to characterize

exceeded that of post-discharge MI, underscoring the

the relative risks of PDB and PDMI on subsequent

frequency and impact of late bleeding events on

mortality, the presence of residual confounders

prognosis after PCI and the importance of tailoring

cannot be excluded.

antiplatelet approaches in patients undergoing PCI
with DES.

CONCLUSIONS
REPRINT REQUESTS AND CORRESPONDENCE: Dr.

In an unrestricted PCI population discharged after

Gregg W. Stone, Columbia University Medical Center,

successful DES implantation, subsequent bleeding

Cardiovascular Research Foundation, 111 East 59th

complications were not uncommon and were strongly

Street, 11th Floor, New York, New York 10022. E-mail:

associated with cardiac and all-cause mortality. The

gs2184@columbia.edu.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-

TRANSLATIONAL OUTLOOK: More research is

DURAL SKILLS: Because bleeding after hospital

needed to develop safer antithrombotic strategies to

discharge following percutaneous coronary intervention

reduce the risk of hemorrhagic complications after

occurs more frequently and has a greater impact on

deployment of drug-eluting coronary stents, especially in

mortality than myocardial infarction, physicians should

patients at high risk of bleeding.

carefully consider the trade-off between risks of ischemic
and bleeding events to individualize the duration and intensity of antiplatelet therapy.
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